Cytomx analysts
WebApr 13, 2024 · This is a summary of recent ratings and recommmendations for CytomX Therapeutics and Stoke Therapeutics, as provided by MarketBeat. CytomX Therapeutics currently has a consensus price target of $3.17, indicating a potential upside of 94.57%. Stoke Therapeutics has a consensus price target of $24.57, indicating a potential upside … WebApr 14, 2024 · CytomX Therapeutics, Inc. ( NASDAQ:CTMX – Get Rating) has been assigned a consensus recommendation of “Hold” from the twelve analysts that are …
Cytomx analysts
Did you know?
WebCytomX Therapeutics Stock (NASDAQ:CTMX), Analyst Ratings, Price Targets, Predictions. Analysts publish ratings and price targets on most stocks. Benzinga tracks … WebAnalyst Coverage. CytomX Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding CytomX Therapeutics, … Annual Reports - Analyst Coverage CytomX Therapeutics, Inc. PD-1 Probody™ Therapeutic Anti-tumor Efficacy and Protection Against … CytomX Therapeutics, Inc. 151 Oyster Point Blvd Suite 400 South San Francisco, CA … Mr. Ogden joined CytomX in August of 2024 after a 16-year tenure at Eli Lilly and … SOUTH SAN FRANCISCO, Calif. , March 22, 2024 (GLOBE NEWSWIRE) -- … Stock Information - Analyst Coverage CytomX Therapeutics, Inc. Events and Presentations - Analyst Coverage CytomX Therapeutics, Inc.
WebApr 14, 2024 · The company has a market cap of £24.70 billion, a P/E ratio of 3,198.81, a PEG ratio of 1.90 and a beta of 0.51. Experian has a 12-month low of GBX 2,242 ($27.76) and a 12-month high of GBX 3,160 ... WebFeb 5, 2024 · When CytomX Therapeutics last reported its balance sheet in September 2024, it had zero debt and cash worth US$236m. Looking at the last year, the company burnt through US$107m. That means it had...
WebThe latest price target for . CytomX Therapeutics (NASDAQ: CTMX) was reported by Mizuho on March 28, 2024.The analyst firm set a price target for $2.00 expecting CTMX to rise to within 12 months ... WebGlassdoor gives you an inside look at what it's like to work at CytomX Therapeutics, including salaries, reviews, office photos, and more. This is the CytomX Therapeutics …
WebLean forward. Agensys Corporation is a small business IT Services firm headquartered in Loudoun County, Virginia. Our proven methodologies allow us to identify, attract and …
WebNasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given … darrell self cort realityWebApr 13, 2024 · We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst … bison is not allowed to be usedWebCompany Type For Profit. Phone Number 6503510353. CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. … darrell shopbell facebookWebMar 31, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX– Get Rating) – Stock analysts at HC Wainwright raised their Q1 2024 earnings per share estimates for CytomX Therapeutics in a report released on... bison is healthyWebBased on analysts offering 12 month price targets for CTMX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . darrell septic river falls wiWebApr 6, 2024 · Find the latest CytomX Therapeutics, Inc. (CTMX) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. darrell scott the open doorWebMar 2, 2024 · InvestorsObserveris giving CytomX Therapeutics Inc (CTMX) an Analyst Rating Rank of 15, meaning CTMX is ranked higher by analysts than 15% of stocks. The average price target for CTMX is $3.564 and analyst’s rate the stock as a Buy. Wall Street analysts are rating CTMX a Buy today. bison is what type of animal